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Background and purpose: Oxidative stress is a central pathogenic mechanism
of Parkinson’s disease (PD), and the heme oxygenase (HO) bilirubin pathway
is one of the main mammalian antioxidative defences. Indeed, there is growing
evidence of HObilirubin upregulation from early phases of PD. Our aim was
to investigate bilirubin as a possible biomarker of PD diagnosis and progres-
sion.
Methods: A cross-sectional casecontrol study was performed to evaluate dif-
ferences in bilirubin levels between newly diagnosed, drug-na€ıve PD subjects
and controls. Afterwards, PD subjects were included in a 2-year longitudinal
study to evaluate disease progression in relation to baseline bilirubin levels.
Results: Seventy-ﬁve de novo PD subjects were selected and matched with 75
controls by propensity score. Analysis of variance showed higher bilirubin lev-
els in PD patients compared with controls (P < 0.001). Linear regression
analysis failed to show a relationship between bilirubin and Uniﬁed Parkin-
son’s Disease Rating Scale (UPDRS) part III (P = 0.283) at baseline evalua-
tion. At 2-year follow-up, indirect relationships between bilirubin levels and
UPDRS part III (P = 0.028) and between bilirubin levels and levodopa-equiv-
alent daily dosage (P = 0.012) were found.
Conclusions: Parkinson’s disease subjects showed higher levels of bilirubin com-
pared with controls. Bilirubin increase might be due to HO overexpression as a
compensatory response to oxidative stress occurring from early stages of PD.
Introduction
Several studies investigating the pathogenic mecha-
nism of Parkinson’s disease (PD) have increasingly
focused on oxidative stress pathways [1]. Oxidative
balance is frequently impaired in PD with subse-
quent damage of proteins, lipids, carbohydrates and
nucleic acids, up to cell death [1,2]. Therefore, iden-
tifying biomarkers of oxidative stress is of primary
importance not only to increase our knowledge on
PD pathogenesis but also to support PD diagnosis
and to track PD motor and non-motor progression
[3].
Amongst diﬀerent oxidative pathways, there is
increasing evidence that heme oxygenase (HO) is one
of the main antioxidative defences in mammalia and
is active since early phases of the adaptive response to
stress [2,4]. Considering that HO converts heme mole-
cules into iron, carbon monoxide and biliverdin that
is further converted to bilirubin by biliverdin reduc-
tase [5], it has been suggested that plasma total biliru-
bin can serve as a marker for HO activity [6] and can
have direct antioxidative properties within the brain
[5–7].
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Considering these ﬁndings, HObilirubin might
represent an additional pathway involved in both PD
pathogenesis and progression. In support of this
hypothesis, there is evidence of a sustained HO upreg-
ulation within dopaminergic cells exposed to oxidative
stress [8,9]. In particular, overexpression of HO might
increase neurotrophic factors, protect neurons from
toxic substances (i.e. methyl-phenyl-tetrahydropyri-
dine) [10] and prevent the toxic aggregation of alpha-
synuclein [9]. Finally, increased bilirubin levels have
been shown in PD patients compared with controls
[11]. However, such results have never been replicated,
fully discussed or related to PD diagnosis and pro-
gression.
The present study aimed to investigate (i) diﬀer-
ences in bilirubin levels between newly diagnosed,
drug-na€ıve PD subjects and healthy controls; (ii) rela-
tionships between bilirubin levels and motor symp-
toms in de novo PD patients at ﬁrst evaluation and
after 2-year follow-up; (iii) relationships between bili-
rubin levels and non-motor symptoms (NMS) in de
novo PD patients at ﬁrst evaluation and after 2-year
follow-up.
Patients and methods
Study design
In the ﬁrst part of the study, a cross-sectional
casecontrol analysis was performed to evaluate dif-
ferences in bilirubin levels between newly diagnosed,
drug-na€ıve PD subjects and healthy controls. In the
second part, PD subjects were included in a 2-year
longitudinal study to evaluate motor and non-motor
progression in relation to baseline bilirubin levels. The
Federico II University Hospital Ethical Committee
approved the study and all subjects provided written
informed consent. The study was performed in accor-
dance with good clinical practice and the Declaration
of Helsinki.
Parkinson’s disease subjects
De novo drug-na€ıve patients with parkinsonism who
were consecutively referred to the Department of Neu-
rosciences at the University Federico II of Naples,
Italy, between 1 January 2008 and 30 June 2009 were
enrolled. Inclusion criteria were the presence of a par-
kinsonian syndrome according to the UK Parkinson’s
Disease Society Brain Bank Diagnostic Criteria
[12,13]; onset <2 years before; and no previous or cur-
rent treatment with dopaminergic drugs. Additional
criteria for inclusion were lack of signiﬁcant cerebral
lesions on magnetic resonance imaging or computed
tomography. Exclusion criteria were a diagnosis of
secondary (such as vascular or drug-induced) or famil-
ial parkinsonism or a diagnosis of atypical parkinson-
ism, according to current diagnostic criteria [14–18].
At baseline evaluation, motor features were evalu-
ated by means of the Uniﬁed Parkinson’s Disease
Rating Scale (UPDRS) part III. Disease duration
(months since reported motor onset) was recorded.
All patients completed the non-motor symptom ques-
tionnaire (NMSQ), a validated tool for detection of
NMS [19]. The NMSQ consists of 30 questions with
dichotomous (yes/no) answers and a total score that
can be determined, with higher scores reﬂecting more
NMS (from 0 to 30). At baseline visit, none of the
patients was treated with anti-parkinsonian drugs,
anticholinergic agents, choline esterase inhibitors, an-
tidepressants, anxiolytic drugs or other centrally act-
ing substances that might have aﬀected both motor
and non-motor evaluation.
Due to the observational nature of the study, after
baseline visit dopaminergic and non-dopaminergic
treatments (i.e. serotoninergic antidepressants) were
then started according to the discretion of each super-
vising physician. After 2 years from enrolment, a clin-
ical evaluation was performed to conﬁrm the
diagnosis of PD. UPDRS part III was evaluated dur-
ing oﬀ phase (12 h oﬀ drugs) and during on state,
and NMS were checked by means of the NMSQ, as
at baseline. Dopaminergic treatment was recorded and
levodopa-equivalent daily dose (LEDD) was calcu-
lated for each drug class [20]. Moreover, for statistical
purposes patients were also classiﬁed as requiring or
not requiring levodopa. Patients taking drugs other
than dopamine agonists, monoamine oxidase inhibi-
tors type B, catechol-O-methyltransferase inhibitors
and levodopa were excluded from the analyses.
Controls
Controls were recruited amongst subjects visiting the
same hospital within the same period for their sched-
uled visit at the Occupational Medicine Unit. Visits
were not related to current health problems but were
performed in accordance with occupational Italian
regulations. Concomitant diseases and treatments
were recorded. All controls underwent physical exami-
nation according to clinical practice.
Laboratory assessment
Serum was collected at baseline visit for both cases and
controls and appropriately stored, in order to be subse-
quently analysed with standardized procedures. In par-
ticular, bilirubin was determined in serum obtained
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from fasting blood by the BILTS method with the CO-
BAS c501 analyser (Roche Diagnostic, Mannheim,
Germany). All subjects were evaluated for possible con-
founding factors in determining bilirubin levels. Exclu-
sion criteria were concomitant liver or gallbladder
disease in clinical records or in standard laboratory
procedures (i.e. aspartate aminotransferase > 35 U/l,
alanine aminotransferase > 35 U/l, gamma-glutamyl
transpeptidase > 36 U/l, presence of HBsAg, presence
of anti-HCV antibody, previous gallbladder removal
surgery, previous gallbladder attack), abnormal choles-
terol or triglyceride metabolism in standard laboratory
procedures (i.e. total cholesterol > 220 mg/dl, triglyce-
rides > 180 mg/dl), use of cholesterol or triglyceride
lowering agents (i.e. statins), recent anaemia or haemol-
ysis in clinical records or in standard laboratory proce-
dures (i.e. haemoglobin < 12 g/dl, haematocrit < 35%
in females or < 37% in males, iron < 45 lg/dl, presence
of reticulocytes in peripheral blood, mean corpuscular
volume <80 ﬂ or >97 ﬂ), abnormal body mass index
(BMI) (overweight, BMI > 25 kg/m2, or underweight,
BMI < 19 kg/m2).
Statistical analysis
First, PD subjects and controls were respectively
extracted from databases of the Department of Neu-
rosciences and of the Occupational Medicine Unit,
according to the exclusion and inclusion criteria, and
matched considering the outcome measure (PD diag-
nosis) and covariates such as age and gender by using
propensity score matching (PSM), with a casecontrol
matching ratio of 1:1. Demographic diﬀerences
between groups were evaluated by v2 or t test, as
appropriate. Diﬀerences in bilirubin levels between
cases and controls were evaluated by t test and subse-
quently analysis of variance (ANOVA) corrected for age
and gender.
In the second part of our study, PD subjects only
were evaluated. For statistical purposes, variables
from diﬀerences in scores of UPDRS part III (D-UP-
DRS-oﬀ and D-UPDRS-on), and NMSQ total score
(D-NMSQ) between 2-year follow-up and baseline
visit were generated. After testing for normal distribu-
tion, linear regression analysis was performed to
assess the relationship between bilirubin levels and
continuous variables (age, disease duration, UPDRS
part III, D-UPDRS-oﬀ, D-UPDRS-on, NMSQ, D-
NMSQ, LEDD). t test and ANOVA analysis were per-
formed to evaluate categorical variables (gender,
requiring or not requiring levodopa). All models were
subsequently adjusted for age and gender. When eval-
uating motor symptoms during on state, analyses were
adjusted for LEDD.
STATA 12.0 and Microsoft Excel 2011 software
were used for data processing and statistical analysis.
Results were considered statistically signiﬁcant for
P < 0.05.
Results
In the ﬁrst part of the study, 75 PD subjects were
selected and matched with 75 healthy controls by
PSM. No signiﬁcant diﬀerences were found in age and
gender between cases and controls (Table 1). Bilirubin
levels were found to be signiﬁcantly higher in PD sub-
jects at t test (P < 0.001) and ANOVA after correction
for age and gender (P < 0.001; adjusted R2 = 0.269)
(Table 1; Fig. 1). In the latter model, gender but not
age appeared to aﬀect bilirubin levels (P = 0.001 and
P = 0.092, respectively), with males presenting higher
levels than females (Table 1).
In the second part of the study, PD subjects only
were evaluated. Considering the baseline visit, linear
regression analysis found no diﬀerent bilirubin levels
in relation to age (P = 0.703) and disease duration
(P = 0.901). The t test conﬁrmed lower bilirubin levels
in females (P = 0.021).
With regard to motor symptoms, linear regression
did not show a relationship between bilirubin levels
and UPDRS part III (P = 0.283) at baseline evalua-
tion; a relationship between these variables only
emerged after correction for age and gender
(P = 0.043; coeﬃcient 0.078; 95% conﬁdence interval
0.001–0.015). Regression analysis failed to show any
diﬀerence in bilirubin levels in relation to D-UPDRS
part III (deﬁned as the diﬀerence between baseline
score and 2-year follow-up evaluation) performed
during oﬀ phase, before (P = 0.114) and after correc-
tion for age and gender (P = 0.714). Regression
analysis showed diﬀerent bilirubin levels in relation to
Table 1 Demographics and serum bilirubin levels of PD cases and
healthy controls, matched by propensity score
PD subjects
(n = 75)
Controls
(n = 75) P values
Age, mean  SD (range) 59.7  7.9
(45–72)
58.7  5.9
(48–69)
0.594
Gender, males / females 45/30 45/30 0.799
Bilirubin levels, mean mg/dl  SD
Males 0.79  0.25 0.58  0.32 0.001
Females 0.64  0.22 0.42  0.20 0.001
Total (range) 0.74  0.25
(0.24–1.32)
0.51  0.29
(0.14–1.62)
<0.001
PD, Parkinson’s disease.
P values are shown from v2, t test or analysis of variance, as appro-
priate.
© 2015 EAN
956 M. MOCCIA ET AL.
D-UPDRS part III performed during on phase before
(P = 0.028; coeﬃcient 0.057; 95% conﬁdence inter-
val 0.001 to 0.016) and after correction for age,
gender and LEDD (P = 0.013; coeﬃcient 0.066;
95% conﬁdence interval 0.001 to 0.013) (Fig. 2).
Linear regression analysis showed a negative relation-
ship between bilirubin levels and LEDD at 2-year fol-
low-up, before (P = 0.012; coeﬃcient 0.053; 95%
conﬁdence interval 0.009 to 0.012) and after cor-
rection for age and gender (P = 0.017; coeﬃcient
0.045; 95% conﬁdence interval 0.001 to 0.008)
(Fig. 3). No diﬀerences were found between subjects
requiring or not requiring levodopa in relation to bili-
rubin levels at t test (P = 0.093) and ANOVA corrected
for age and gender (P = 0.071).
When analysing NMS, linear regression models
failed to show any diﬀerence in bilirubin levels in rela-
tion to NMSQ total score at baseline before
(P = 0.631) and after correction for age and gender
(P = 0.368), and to D-NMSQ before (P = 0.765) and
after correction for age and gender (P = 0.462).
Discussion
This is the ﬁrst study speciﬁcally designed to investi-
gate diﬀerences in bilirubin levels between newly diag-
nosed, drug-na€ıve PD subjects and healthy controls,
and to evaluate bilirubin levels in relation to clinical
progression of PD.
Considering the main objective of the present study,
increased bilirubin levels in PD patients compared
with controls were found. Our results are in line with
previous ﬁndings by Scigliano and colleagues [11].
Accordingly, it is speculated that HO upregulation
within the substantia nigra might be an adaptive
response to increased oxidative stress occurring in PD
[9] and is likely to be responsible for increased biliru-
bin levels [9]. Interestingly, circulating bilirubin is in
Figure 1 Box and whisker plot showing the diﬀerence in biliru-
bin levels between cases and controls. Parkinson’s disease (PD)
subjects presented higher bilirubin levels than healthy controls at
t test (P < 0.001) and analysis of variance corrected for age and
gender (P < 0.001).
(a)
(b)
Figure 2 Scatter plot showing the relationships between bilirubin
and Uniﬁed Parkinson’s Disease Rating Scale (UPDRS) part III
performed at baseline (a) and at 2-year follow-up during on state
(D-UPDRS) (b). P values are shown from linear regression analysis.
Figure 3 Scatter plot showing the relationships between bilirubin
and levodopa-equivalent daily dosage (LEDD). P value is shown
from linear regression analysis.
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dynamic equilibrium with extravascular tissues,
including the central nervous system [21], and PD sub-
jects do not present any diﬀerence in peripheral HO-1
mRNA levels evaluated in blood mononuclear cells
[22]. Therefore increased bilirubin production within
the brain may be responsible for systemic bilirubin
variations. Moreover, as HO upregulation occurs
since ﬁrst PD diagnosis, it can be part of early patho-
logical mechanisms underlying PD.
With regard to the relationships amongst bilirubin
levels and clinical variables at baseline evaluation,
slightly worse motor symptoms were found in PD
patients with higher bilirubin levels. Sustained HO
immunoreactivity is observed in dopaminergic neurons
of PD patients where cytoplasmic Lewy bodies dis-
played intense peripheral HO staining [9,23,24]. It has
been found that chronic upregulation of HO in the
PD brain may exacerbate the degenerative process by
promoting iron deposition and oxidative mitochon-
drial damage [9], explaining the baseline relationship
between motor symptom severity and higher bilirubin
levels. However, upregulation of HO in the PD sub-
stantia nigra may also represent an adaptive response,
and may at least in part counteract the impact of
motor symptoms by preventing the toxic aggregation
of alpha-synuclein. In this view, HO inducibility and
subsequent bilirubin levels may correlate with
improved health outcomes [6].
At 2-year follow-up evaluation, PD subjects with
higher bilirubin levels required fewer dopaminergic
drugs and, at least as a trend, less levodopa, and pre-
sented lower motor scores during on state despite sim-
ilar motor scores during oﬀ. The latter result is
intriguing and could at least in part be attributed to
potential interactions between drug pharmacokinetics
and bilirubin levels at the peripheral level.
Afterwards, no relationship was found between
bilirubin levels and NMS presence or progression.
However, further investigations on larger populations
should be strongly encouraged by means of the NMS
scale, which was unfortunately still not available when
the present study was designed [19].
Finally, some limitations need to be addressed. First,
the sample size is small and data generalizability can be
diﬃcult. Further studies on larger populations are
needed to speciﬁcally address the unmet issues (i.e.
NMS and bilirubin levels). In addition, bilirubin varia-
tions during PD course were not evaluated. Two previ-
ous studies investigated this issue and found lower
bilirubin levels in Alzheimer’s disease [7,25]. However,
both studies included subjects with diﬀerent disease
durations. As variability in bilirubin levels during the
time course of the disease cannot be excluded, subjects
with possible confounding factors were excluded from
the analysis. Furthermore, although highly selective
inclusion criteria for both cases and controls were used,
the presence of other factors possibly interfering with
bilirubin levels cannot be completely excluded. Finally,
it has to be reported that bilirubin presents a selective
neurotoxicity for basal ganglia, as it occurs in kernicte-
rus; however, our population did not present bilirubin
levels as high as required to be directly neurotoxic [21].
In conclusion, our ﬁndings support the fact that bili-
rubin levels may diﬀerentiate PD subjects from healthy
controls, possibly because HO overexpression is a com-
pensatory response to oxidative stress, occurring from
early stages of PD. The antioxidant eﬃcacy of increased
bilirubin levels is evident at 2-year follow-up when PD
subjects with higher bilirubin levels presented better
motor outcomes, suggestive of more preserved dopami-
nergic pathways. In this view, the inducibility of the
HO pathway could represent an important compensa-
tory mechanism in PD with signiﬁcant eﬀects on disease
progression. In addition, it may be hypothesized that
the inducibility of HO can be an important mechanism
predisposing the senescent nervous system to PD and to
other neurodegenerative disorders [9]. The latter is pos-
sibly due to diﬀerent mechanisms such as iron deposi-
tion or mitochondrial damage [9], and it has recently
been conﬁrmed by the ﬁnding of increased PD risk in
subjects presenting HO gene variations [26]. As a conse-
quence, measures increasing intracellular bilirubin (i.e.
administration of biliverdin or of HO inducers) or mim-
icking its activity (i.e. administration of phycocyanobi-
lin) should be investigated.
The present study broadens our knowledge of oxi-
dative stress in PD and suggests that bilirubin may
provide useful diagnostic and prognostic information
in this disorder. Further studies should be speciﬁcally
addressed to evaluating variations in bilirubin levels
during disease course and possible pathophysiological
and clinical consequences.
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